TM
Titan‑1 Technology: A New Era of Microbiome Precision
Sample-to-Insight Microbiome Platform for Advanced Diagnostics
TM
Titan‑1™ Technology: A New Era of Microbiome Precision
AI-Powered Microbiome Discovery for the Future of Health
Titan‑1™ is not only transforming personal health through GutID™, but it’s also driving major advances in clinical research and precision medicine.
Titan‑1™ is Intus Biosciences’ advanced microbiome technology platform, built to be high resolution, high throughput, and database independent. By sequencing beyond 16S and combining results with proprietary AI analysis, it delivers highly accurate, actionable insights that surpass the limits of traditional microbiome testing.
With full control over every step—from sample lysis to deep AI-driven interpretation—Titan‑1™ functions as a true ‘sample to solution’ platform. This integrated approach enables precise strain-level detection, reveals novel microbes, and sets a new standard for microbiome research, diagnostics, and therapeutic development.
The Technology Behind Titan-1™
High-Resolution Amplicon Sequencing
Titan-1™ delivers precise species and strain identification, providing a detailed view of the microbiome that unlocks deeper insights into health, disease, and therapeutic potential.
AI-Driven
Bioinformatics
Our advanced machine learning algorithms analyze complex data with speed and accuracy, transforming raw sequences into actionable insights for diagnostics, treatment, and research.
High Sensitivity with Fast Turnaround
Titan-1™ detects even low-abundance microbes with exceptional sensitivity and specificity, delivering comprehensive results in just days to accelerate decision-making and discovery.
Clinical
Standards
Built to meet the highest scientific and clinical standards, Titan-1™ ensures consistent, validated results that are trusted by pharmaceutical partners and research institutions alike.
Strain-Level Precision Through Innovation
What sets Titan‑1™ apart is its unparalleled resolution and scalability. While traditional methods might detect broad microbial categories, Titan‑1™ provides actionable, strain-level data that can reveal key health indicators, such as distinguishing a harmful strain of E. coli from a commensal one. Its ability to identify and monitor novel microbial strains has broad implications across gut health, immunity, longevity, and even cancer and disease diagnostics.
Additionally, the AI-enhanced analytics pipeline allows Titan‑1™ to track microbiome shifts over time, offering clinicians, researchers, and consumers the ability to understand not just what microbes are present, but how they’re evolving and interacting in the context of disease or therapy.
